Lincoln Pharma posts net profit of Rs 13.37 crore for the Q3 FY21

Net revenue for the Q3 FY21 was reported at Rs 113.26 crore

Lincoln Pharmaceuticals has reported a net profit of Rs 13.37 crore for the Q3 FY21 ended December 2020 as against a net profit of Rs 10.18 crore in the corresponding period last year, growth of 31.35 per cent. Net revenue for the Q3 FY21 was reported at Rs 113.26 crore, higher by 15.56 per cent over previous fiscal’s same period net revenue of Rs 98.01 crore. The company reported EBITDA of Rs 19.94 crore in Q3FY21, a rise of 43.25 per cent as compared to Rs 13.92 crore in the corresponding period last year. EPS for Q3FY21 was at Rs 6.68 per share for as compared to Rs 5.09 in the corresponding period last year.

Mahendra Patel, MD, Lincoln Pharmaceuticals, said, “On the back of strong domestic and international business, the company posted 15.56 per cent sales growth, 4 per cent rise in exports and 31.35 per cent rise in the PAT for the quarter ended Q3FY21. Exports sales in nine months ended December 2020 was reported at Rs 212.47 crore, growth of 17.56 per cent Y-o-Y. Geographical and product expansion coupled with operational efficiency contributing to the growth. The company is in the process of expanding its presence in Africa, South East Asian countries and exploring entry in the EU. Expanding the product basket, the company will be introducing six to seven new products in the domestic markets and expects 20-25 new dossiers approval for the exports market.